Rice Hall James & Associates LLC Reduces Holdings in iRadimed Corporation $IRMD

Rice Hall James & Associates LLC reduced its position in shares of iRadimed Corporation (NASDAQ:IRMD) by 31.9% during the third quarter, HoldingsChannel reports. The firm owned 43,593 shares of the medical equipment provider’s stock after selling 20,429 shares during the quarter. Rice Hall James & Associates LLC’s holdings in iRadimed were worth $3,102,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. CWM LLC increased its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the period. Tower Research Capital LLC TRC boosted its position in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of iRadimed during the second quarter valued at about $60,000. Quantbot Technologies LP purchased a new stake in shares of iRadimed during the first quarter worth about $78,000. Finally, Comerica Bank increased its position in shares of iRadimed by 21.4% during the first quarter. Comerica Bank now owns 2,288 shares of the medical equipment provider’s stock worth $120,000 after acquiring an additional 404 shares during the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IRMD. Zacks Research raised iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reiterated a “buy” rating and set a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Roth Capital set a $90.00 price target on shares of iRadimed in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 22nd. Finally, Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Trading Up 0.4%

Shares of NASDAQ IRMD opened at $97.45 on Friday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of 59.06 and a beta of 1.06. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $98.44. The business has a 50 day simple moving average of $88.72 and a 200-day simple moving average of $74.24.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently declared a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Insider Transactions at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the sale, the chief financial officer owned 7,362 shares in the company, valued at $716,248.98. This represents a 67.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $96.73, for a total transaction of $483,650.00. Following the completion of the transaction, the chief executive officer directly owned 2,287,500 shares in the company, valued at $221,269,875. This represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 65,000 shares of company stock valued at $5,548,150. Insiders own 36.80% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.